All In Biotech

Drug Trial Radar · NCT04959981

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

A Phase 1b Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Non-Small-Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 2, 2021

Primary completion

Apr 27, 2023

Study completion Apr 27, 2023

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Jul 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung cancer (NSCLC). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 or ERAS-601 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer

Interventions

  • ERAS-007Drug

    Administered orally

  • ERAS-601Drug

    Administered orally

  • OsimertinibDrug

    Administered orally

  • SotorasibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 22
  2. Maximum Tolerated Dose (MTD)Time frame: Study Day 1 up to Day 22
  3. Recommended Dose (RD)Time frame: Study Day 1 up to Day 22
  4. Adverse EventsTime frame: Assessed up to 24 months from time of first dose

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UC Irvine, Chao Family Comprehensive Cancer Center

    Orange, California

  • UC Los Angeles

    Santa Monica, California

  • University of Colorado

    Aurora, Colorado

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Research Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Hackensack University Medical Center (John Theurer Cancer Center)

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Sarah Cannon Research Institute (Tennessee Oncology)

    Nashville, Tennessee

  • Virginia Cancer Specialists

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.